Mesoblast LtdShs Aktie
| 1,16EUR | -0,01EUR | -0,85% |
WKN: A0DNPW / ISIN: AU000000MSB8
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 102 | 83 | 77 | 83 | 73 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,46 | 0,12 | 0,18 | 0,13 | 0,12 |
Bilanz (in Mio. AUD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 198 | 197 | 102 | 123 | 129 |
| Summe Anlagevermögen | 982 | 901 | 990 | 883 | 872 |
| Summe Aktiva | 1 180 | 1 099 | 1 091 | 1 006 | 1 002 |
Bilanz (in Mio. AUD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 383 | 324 | 368 | 252 | 283 |
| Summe Eigenkapital | 798 | 774 | 723 | 754 | 719 |
| Summe Passiva | 1 180 | 1 099 | 1 091 | 1 006 | 1 002 |
Adresse
| 55 Collins Street, 3000 Melbourne | |
| Telefon | +61 (3) 9639-6036 |
| Fax | +61 (3) 9639-6030 |
| Internet | http://www.mesoblast.com |
Management
|
Andrew Chaponnel
Chief Financial Officer |
|
Dagmar Rosa-Bjorkeson
Chief Operating Officer |
|
Eric A. Rose
Executive Director & Chief Medical Officer |
|
Geraldine Storton
Head-Regulatory Affairs & Quality Management |
|
Gregory George
Director |
|
Jane C. Bell
Independent Non-Executive Chairman |
|
Jonathan Richard Symonds
Head-Corporate Finance & Strategy |
|
Michael Schuster
Head-Pharma Partnering |
|
Niva Sivakumar
Joint Secretary |
|
Paul Hughes
Joint Secretary & Head-Investor Relations Contact |
|
Paul Simmons
Head-Research & New Product Development |
|
Peter T. Howard
General Counsel & Corporate Executive |
|
Philip James Facchina
Independent Non-Executive Director |
|
Philip R. Krause
Independent Non-Executive Director |
|
Silviu Itescu
Chief Executive Officer, Executive Director & MD |
|
William Matt Burns
Independent Non-Executive Vice Chairman |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.